Kanyerere, H; Girma, B; Mpunga, J; Tayler-Smith, K; Harries, AD; Jahn, A; Chimbwandira, FM (2016) Scale-up of ART in Malawi has reduced case notification rates in HIV-positive and HIV-negative tuberculosis. Public Health Action, 6 (4). pp. 247-251. ISSN 2220-8372 DOI: 10.5588/pha.16.0053

Downloaded from: http://researchonline.lshtm.ac.uk/3404167/

DOI: 10.5588/pha.16.0053

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Scale-up of ART in Malawi has reduced case notification rates in HIV-positive and HIV-negative tuberculosis

H. Kanyerere, B. Girma, J. Mpunga, K. Tayler-Smith, A. D. Harries, A. Jahn, F. M. Chimbwandira

Setting: For 30 years, Malawi has experienced a dual epidemic of human immunodeficiency virus (HIV) infection and tuberculosis (TB) that has recently begun to be attenuated by the scale-up of antiretroviral therapy (ART).

Objective: To report on the correlation between ART scale-up and annual national TB case notification rates (CNR) in Malawi, stratified by HIV-positive and HIV-negative status, from 2005 to 2015.

Design: A retrospective descriptive ecological study using aggregate data from national reports.

Results: From 2005 to 2015, ART was scaled up in Malawi from 28,470 to 618,488 total patients, with population coverage increasing from 2.4% to 52.2%. During this time, annual TB notifications declined by 35%, from 26,344 to 17,104, and the TB CNR per 100,000 population declined by 49%, from 206 to 105. HIV testing uptake increased from 51% to 92%. In known HIV-positive TB patients, the CNR decreased from a high of 1247/100,000 to 710/100,000, a 43% decrease. In known HIV-negative TB patients, the CNR also decreased, from a high of 66/100,000 to 49/100,000, a 26% decrease.

Conclusion: TB case notifications have continued to decline in association with ART scale-up, with the decline seen more in HIV-positive than HIV-negative TB. These findings have programmatic implications for national TB control efforts.

Methods

Study design
This was a retrospective descriptive ecological study using aggregate data from national reports.

Setting
Malawi is one of the poorest countries in the world, with a rapidly growing population currently estimated at 17 million and a gross national income per capita of US$730. National scale-up of ART commenced in 2004, with the number of patients alive and retained on treatment reported quarterly by the HIV Department of the Ministry of Health (Lilongwe). In line with national and international guidelines, PLHIV are currently eligible for ART if they are pregnant or breastfeeding, have World Health Organization (WHO) clinical Stage 3 or 4 disease, or have a CD4 cell count below the nationally agreed threshold (≤250 cells/μl before 2010, ≤350 cells/μl between 2010 and 2014 and ≤500 cells/μl thereafter). At the start of national scale-up, first-line treatment mainly consisted of a fixed-dose combination of stavudine-lamivudine-nevirapine; from 2011 there was a gradual countrywide change to tenofovir-lamivudine-efavirenz.

Acknowledgements
The authors thank La Fondation Veuve Emile Metz-Fesch (Luxembourg) for their support for the open access publication costs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Conflict of interest: none declared.

Key words
antiretroviral therapy; TB; Malawi; human immunodeficiency virus; HIV/AIDS
preventive therapy for patients found to be HIV-positive.\textsuperscript{17,18} HIV testing of TB patients was routinely scaled up, with uptake and results of testing formally and routinely captured at the national level from 2005 onwards.

\textbf{Study population}

The study population included the estimated annual number of PLHIV in Malawi, the number (adults and children) recorded alive and retained on ART at the end of each year, and all adults and children registered nationally each year with TB, stratified by HIV status, from 2005 to 2015.

\textbf{Sources of data, variables and analysis}

Sources of aggregate data were the national annual reports from the NTP and the HIV Department, Ministry of Health, Malawi. With the changes in ART eligibility criteria during the study period, ART coverage was calculated using the total HIV-infected population as the denominator. This was derived from national epidemiological projections using the Estimation and Projection package and Spectrum software from the Joint United Nations Programme on AIDS (UNAIDS, Geneva, Switzerland)\textsuperscript{19} and based on national population estimates obtained from the Malawi National Statistics Office (http://www.nsomalawi.mw/publications.html). Annual TB case notifications were documented and TB case rates per 100,000 population were derived from national population estimates. TB patients included registered cases stratified by HIV status: known HIV-positive, known HIV-negative and unknown HIV status. The numbers of patients with known HIV-positive TB and with known HIV-negative TB/100,000 HIV-positive and HIV-negative Malawi populations, respectively, were calculated based on the annual data from the UNAIDS Spectrum software and the Malawi National Statistics Office, as described above.\textsuperscript{19} Data were analysed descriptively.

\textbf{Ethics approval}

Ethics approval for the study was obtained from the Malawi National Health Science Research Committee (Lilongwe). The Ethics Advisory Group of the International Union Against Tuberculosis and Lung Disease (Paris, France) waived the need for further international ethics approval. As records and reports of aggregate data were used, informed patient consent was not necessary.

\textbf{RESULTS}

The number of people alive and receiving ART from 2005 to 2015 increased progressively from 28,470 to 618,488, with ART coverage among PLHIV rising from 2.4\% to 52.2\% (Figure 1).

The trends in TB case notifications and TB CNR (/100,000) are shown in Figure 2. Absolute numbers of TB cases peaked in 2006.
at 26,344 and had declined progressively to 17,104 by 2015, a 35% decrease. This trend was mirrored by a decline in the TB CNR, from a high of 206/100,000 in 2006 to 105/100,000 in 2015, a 49% decrease.

Trends in absolute numbers of notified TB patients who were HIV-tested, along with HIV status and, for those known to be HIV-positive, the uptake of ART, are shown in Figure 3. The proportion of TB patients who were HIV-tested in the country increased from 51% in 2005 to 92% in 2015, and was stable between 2012 and 2015 (92–93%). The proportion of TB patients with positive HIV status declined from 69% in 2005 to 53% in 2015, with the period 2010–2015 seeing a continual year-on-year decline from 64% to 53%. The proportion of HIV-positive TB patients started on ART remained at <50% between 2005 and 2009, but increased progressively from 2010 onwards, from 54% to 94% in 2015. For the 7 years when HIV testing rates were >85% (2009–2015), the absolute number of HIV-positive TB patients decreased from 13,558 to 8,408 (a 38% decrease), while the overall change in absolute numbers of HIV-negative TB patients was small, decreasing from 7,483 to 7,420 (a 0.7% decrease).

Trends in HIV-positive TB cases /100,000 PLHIV and HIV-negative TB cases /100,000 people not infected with HIV are shown in Figure 4A and B. The initial increase in CNR/100,000 in the first 3 years reflects the progressive increase in TB patients being HIV tested, from 51% to 65% to 83%. Thereafter, HIV testing rates were always >83%. In known HIV-positive TB patients, there was a progressive decrease in the CNR, from a high of 1247/100,000 in 2007 to 710/100,000 in 2015, a 43% decrease. In known HIV-negative TB patients, there was also a decrease in the CNR from a high of 66/100,000 in 2008 to 49/100,000 in 2015, a 26% decrease.

**DISCUSSION**

This study has a number of interesting findings. First, our initial reports from Malawi on the pronounced inverse correlation between the national scale-up of ART and national TB case notifications are confirmed.10,12 As ART coverage increases, the absolute
numbers of TB cases and the TB CNR/100 000 have continued to decline. This is in line with other reports and publications from southern Africa.11

Second, the proportion of TB patients being tested for HIV is now consistently greater than 90%, and in the last 2 years over 90% of patients with HIV-associated TB have been initiated on ART. We have no information from this aggregate data set about the time of starting ART, or indeed whether ART was already being taken at the time TB was diagnosed. Nevertheless, having PLHIV on ART during anti-tuberculosis treatment should improve TB treatment outcomes—provided there is no resistance to the antiretroviral drugs—and should also help to prevent recurrent TB developing after successful completion of anti-tuberculosis treatment.8,20

Third, while there has been a large decrease in the absolute number and proportion of HIV-infected TB patients in the last 7 years, the decrease in absolute numbers of TB patients without HIV infection was marginal. However, when TB-HIV status was assessed in relation to the CNR/100 000, there were large decreases both in HIV-positive TB cases/100 000 PLHIV and in the CNR in HIV-negative TB cases/100 000 people without HIV, although these decreases were less marked compared with HIV-positive cases. These results confirm our first and preliminary findings in Malawi for 2012,20 and suggest that a reduction in HIV-positive TB cases has a beneficial effect on transmission of *M. tuberculosis* in the community and thus fewer cases of TB in the non-HIV-infected population. Similar findings have recently been reported from a 15-year observational study in Kenya, where there was a 28–44% decrease in HIV-positive TB and an 11–26% decrease in HIV-negative TB.21

The strengths of this study are the comprehensive national reports, which for TB have integrated HIV parameters since 2005, and the recognised quality of Malawi’s ART data.22 The limitations relate mainly to the aggregate nature of the data, which rely on accurate TB case notifications from Malawi’s many TB registration centres, and which prevent detailed examination and explanation of some of the observations, such as time of ART initiation in HIV-infected TB patients. We also cannot exclude the possibility that the decrease in TB notifications might have occurred as a result of other changes in the last 12 years, such as improved socio-economic status, better coverage or quality of TB diagnosis, or implementation of isoniazid preventive therapy (IPT). However, we have no evidence of any marked improvement in socio-economic conditions of the rural population. Changes in coverage or quality of TB diagnosis, such as the introduction of Xpert® MTB/RIF (Cepheid, Sunnyvale, CA, USA), might have been expected to increase rather than reduce TB case notifications, and to date there has been no significant scale-up of IPT.

There are some important implications for moving forward. First, in line with the WHO’s rapid advice in 2015 and recently released 2016 guidelines to start all PLHIV on ART regardless of clinical stage or CD4 cell count,23,24 Malawi has made a strategic decision to start what is called ‘HIV test and treat’. Early start of ART has been shown to further reduce the risk of TB in PLHIV,4,7 and this should enhance the gains already made in the past several years. TB is also a major cause of hospitalisation and in-hospital mortality in adults and children globally, and early ART is likely to substantially reduce this burden.25

Second, there are plans to scale up IPT in a phased manner around the country. Two randomised controlled studies in Ivory Coast and South Africa have demonstrated that adding IPT to ART in PLHIV can lead to an additional reduction in TB cases of 30% or higher,7,26 and this intervention may add to the TB preventive effect of ART. This is important because despite the effective intervention of ART, TB CNRs in PLHIV are still much higher than in the non-HIV-infected population.

Third, with HIV-negative TB cases decreasing, but at a relatively slow rate, it is important that the Malawi NTP attend to the basics of TB control, including good infection control, measures to minimise the risk of multidrug-resistant TB and the provision of regular structured supportive supervision for all the registration units in the country.27

Fourth, Malawi needs to start recognising and addressing other factors that increase the risk of TB, such as undernutrition, smoking, alcohol and diabetes mellitus.28 Rapid uncontrolled urbanisation together with major lifestyle changes among populations in sub-Saharan Africa are driving a rapidly increasing epidemic of diabetes mellitus,29 and there is increasing evidence to show that this poses a risk for TB control in terms of rising case numbers and worse treatment outcomes for people undergoing anti-tuberculosis treatment.30

In conclusion, this study provides further evidence of the continuing decline in TB notifications in association with the scale-up of ART in Malawi. There is a large decline in CNRs in HIV-positive TB, although rates are still high compared with the HIV-negative population. CNRs are declining in HIV-negative TB, albeit slowly. While efforts towards scaling up ART must continue to ensure the wide coverage and early start of treatment for PLHIV, Malawi must ensure that it provides high quality core services for TB, and it should also begin to address other determinants of the disease.

**References**
